Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling

Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modeling

Objective To determine whether unsupervised principal component analysis (PCA) of comprehensive clinico-radiologic data can identify phenotypic subgroups within antibody-negative patients with overlapping features of multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSDs), and t...

Bibliografski detalji
Glavni autori:	Yeo, T, Probert, F, Jurynczyk, M, Sealey, M, Cavey, A, Claridge, TDW, Woodhall, M, Waters, P, Leite, MI, Anthony, DC, Palace, J
Format:	Journal article
Jezik:	English
Izdano:	Lippincott, Williams & Wilkins (LWW) 2019

Slični predmeti

RELAPSING AQP4 ANTIBODY NEGATIVE NMO WITH MOG ANTIBODIES
od: Elsone, L, i dr.
Izdano: (2014)

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease.
od: Jurynczyk, M, i dr.
Izdano: (2017)

Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease
od: Jurynczyk, M, i dr.
Izdano: (2017)

Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
od: Piccolo, L, i dr.
Izdano: (2016)

Overlapping CNS inflammatory diseases: differentiating features of NMO and MS.
od: Juryńczyk, M, i dr.
Izdano: (2015)

Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis
od: Probert, F, i dr.
Izdano: (2021)

Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach
od: Yeo, T, i dr.
Izdano: (2021)

A blood-based metabolomics test to distinguish relapsing–remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application
od: Yeo, T, i dr.
Izdano: (2020)

Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model
od: Yeo, T, i dr.
Izdano: (2022)

Glycine receptor antibody — a marker for NMO/ NON-MS demyelination?
od: Hamid, S, i dr.
Izdano: (2015)

MOG-IGG IN NMO AND NMO-LIKE DISORDERS
od: Luppe, S, i dr.
Izdano: (2014)

A novel sensitive assay for aqueporin-4 antibodies (NMO-IgG)
od: Waters, P, i dr.
Izdano: (2007)

Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes
od: Juryńczyk, M, i dr.
Izdano: (2015)

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
od: Sato, D, i dr.
Izdano: (2014)

Metabolomic biomarkers in blood samples identify cancers in a mixed population of patients with nonspecific symptoms
od: Larkin, JR, i dr.
Izdano: (2022)

Seronegative NMO: a sensitive AQP4 antibody test clarifies clinical features and next challenges.
od: Fujihara, K, i dr.
Izdano: (2013)

Distinguishing the brain MRI features of MS, AQP4-and MOG-antibody disease.
od: Jurynczyk, M, i dr.
Izdano: (2016)

Spinal cord MRI features in neuromyelitis optica (NMO): characteristics and relationship with severity and recovery in longitudinally extensive transverse myelitis (LETM) attacks
od: Murchison, A, i dr.
Izdano: (2013)

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete?
od: Downer, J, i dr.
Izdano: (2012)

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: Is MRI obsolete?
od: Downer, J, i dr.
Izdano: (2012)

Frequency of Aqp4-Ab in patients with neuromyelitis optica (Devic's syndrome) is higher than predicted by NMO-IgG testing
od: Jarius, S, i dr.
Izdano: (2007)

International multicenter examination of MOG antibody assays
od: Reindl, M, i dr.
Izdano: (2020)

Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab.
od: Kitley, J, i dr.
Izdano: (2014)

Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab
od: Kitley, J, i dr.
Izdano: (2014)

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
od: Waters, P, i dr.
Izdano: (2016)

Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.
od: Waters, P, i dr.
Izdano: (2012)

A case of MS, ADEM, NMO or all three?
od: Pomeroy, I, i dr.
Izdano: (2005)

NMO-IgG/Aqp4-Ab belongs to the IgG1 subclass and activates complement in vitro
od: Jarius, S, i dr.
Izdano: (2007)

Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of clinically defined MS from non-MS patients with CSF oligoclonal bands
od: Probert, F, i dr.
Izdano: (2022)

Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders.
od: Sato, D, i dr.
Izdano: (2013)

Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.
od: Matthews, L, i dr.
Izdano: (2013)

The two faces of NMO
od: Schwarz, B, i dr.
Izdano: (2017)

NMO-IgG in the diagnosis of neuromyelitis optica.
od: Jarius, S, i dr.
Izdano: (2007)

Aquaporin-4 Antibody Isoform Binding Specificity Does Not Explain Clinical Variations in Neuromyelitis Optica
od: Kitley, J, i dr.
Izdano: (2013)

Characterization of NMO and NMOSD Patients with a Late Onset
od: Collongues, N, i dr.
Izdano: (2013)

Antibodies to aquaporin-1 are not present in neuromyelitis optica
od: Waters, P, i dr.
Izdano: (2015)

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
od: Kezuka, T, i dr.
Izdano: (2014)

An audit of the diagnostic usefulness of the NMO-IgG assay for neuromyelitis optica
od: Littleton, E, i dr.
Izdano: (2006)

Glycine receptor antibodies: Clinical spectrum and pathogenic mechanisms of the antibodies
od: Carvajal, A, i dr.
Izdano: (2012)

Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model
od: Yeo, Tianrong, i dr.
Izdano: (2022)